The aldo-keto reductase 1C3 (AKR1C3) enzyme is considered an attractive target in Castration Resistant Prostate Cancer (CRPC) because of its role in the biosynthesis of androgens. Flufenamic acid, a non-selective AKR1C3 inhibitor, has previously been subjected to bioisosteric modulation to give rise to a series of compounds with the hydroxytriazole core. In this work, the hit compound of the previous series has been modulated further, and new, more potent, and selective derivatives have been obtained. The poor solubility of the most active compound (cpd 5) has been improved by substituting the triazole core with an isoxazole heteronucleous, with similar enzymatic activity being retained. Potent AKR1C3 inhibition is translated into antiproliferative effects against the 22RV1 CRPC cellular model, and the in-silico design, synthesis and biological activity of new compounds are described herein. Compounds have also been assayed in combination with two approved antitumor drugs, abiraterone and enzalutamide.

New aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffold

Pippione A. C.;Kovachka S.;Sainas S.;Rolando B.;Denasio E.;Adinolfi S.;Zonari D.;Lolli M. L.;Spyrakis F.;Oliaro-Bosso S.;Boschi D.
2022

Abstract

The aldo-keto reductase 1C3 (AKR1C3) enzyme is considered an attractive target in Castration Resistant Prostate Cancer (CRPC) because of its role in the biosynthesis of androgens. Flufenamic acid, a non-selective AKR1C3 inhibitor, has previously been subjected to bioisosteric modulation to give rise to a series of compounds with the hydroxytriazole core. In this work, the hit compound of the previous series has been modulated further, and new, more potent, and selective derivatives have been obtained. The poor solubility of the most active compound (cpd 5) has been improved by substituting the triazole core with an isoxazole heteronucleous, with similar enzymatic activity being retained. Potent AKR1C3 inhibition is translated into antiproliferative effects against the 22RV1 CRPC cellular model, and the in-silico design, synthesis and biological activity of new compounds are described herein. Compounds have also been assayed in combination with two approved antitumor drugs, abiraterone and enzalutamide.
237
114366
114384
https://www-scopus-com.bibliopass.unito.it/record/display.uri?eid=2-s2.0-85128267024&origin=resultslist&sort=plf-f&src=s&st1=10.1016/j.ejmech.2022.114366&sid=07f6cd37fbeafef783a3f166320d8feb&sot=b&sdt=b&sl=33&s=DOI(10.1016/j.ejmech.2022.114366)&relpos=0&citeCnt=0&searchTerm=&featureToggles=FEATURE_NEW_DOC_DETAILS_EXPORT:1
AKR1C3 inhibitors, prostate cancer, triazoles, aldo-keto reductase
Pippione A.C.; Kilic-Kurt Z.; Kovachka S.; Sainas S.; Rolando B.; Denasio E.; Pors K.; Adinolfi S.; Zonari D.; Bagnati R.; Lolli M.L.; Spyrakis F.; Oliaro-Bosso S.; Boschi D.
File in questo prodotto:
File Dimensione Formato  
2022_AKR1C3 triazoli.pdf

non disponibili

Descrizione: Articolo principale
Tipo di file: PDF EDITORIALE
Dimensione 2.72 MB
Formato Adobe PDF
2.72 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Revised Pippione et al AKR1C3.pdf

accesso aperto

Descrizione: Articolo principale
Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 7.67 MB
Formato Adobe PDF
7.67 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1859921
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact